ArticleRadiology case reports2026
Isolated bilateral breast myeloid sarcoma: A rare case report.
Article in Radiology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloid sarcoma (MS) is a rare extramedullary tumor composed of immature myeloid cells that is most associated with acute myeloid leukemia (AML), whereas isolated bilateral breast involvement without bone marrow disease is exceptionally uncommon. We report the case of a 38-year-old woman who presented with bilateral breast masses, both classified as BI-RADS 5 on imaging. Ultrasound-guided core needle biopsies of both breast lesions established the diagnosis of myeloid sarcoma, with immunohistochemical positivity for MPO, CD34, CD56, and CD117. Peripheral blood and bone marrow examinations showed no evidence of AML, and FDG PET/CT confirmed isolated extramedullary disease, providing accurate staging and monitoring treatment response. The patient received AML-type induction chemotherapy followed by salvage FLAG-IDA chemotherapy for residual disease and consolidative radiotherapy, achieving complete metabolic remission that was maintained at 6-month follow-up. This case highlights the diagnostic challenges of isolated bilateral breast myeloid sarcoma and emphasizes that histopathological confirmation with immunohistochemistry, complemented by FDG PET/CT, is important for accurate diagnosis, staging, treatment assessment, and multidisciplinary management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.